Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chia-Chi Lin

Showing results (1-10 of 231) with videos related to

Pageof 24
Sort By:
Chinese Clinical Oncology|July 18, 2019
Challenges of the phase I drug development in non-small cell lung cancerChia-Chi Lin
Journal of the Formosan Medical Association = Taiwan Yi Zhi|November 29, 2011
RET mutations and medullary thyroid cancerChia-Chi Lin
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Clinical Development of Colony-Stimulating Factor 1 Receptor (CSF1R) InhibitorsChia-Chi Lin
Cancer Prevention Research (Philadelphia, Pa.)|January 6, 2025
Passing the Torch forward: Moving beyond EGFR Inhibition in NMIBC PreventionTsung-Che Wu, Chia-Chi Lin
Targeted Oncology|April 4, 2009
Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancerChia-Chi Lin, Chih-Hsin Yang
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2022
Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase InhibitorsTsung-Che Wu, Chia-Chi Lin
Trends in Biotechnology|January 4, 2025
Bacterial proteome microarray technology in biomedical researchChia-Chi Lin, Chien-Sheng Chen
Drugs|December 24, 2010
Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutationsChia-Chi Lin, James Chih-Hsin Yang
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Active tuberculosis during temsirolimus and bevacizumab treatmentChia-Chi Lin, Jann-Yuan Wang, Yeong-Shiau Pu
Discovery Medicine|July 1, 2010
Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancerYu-Yun Shao, Chia-Chi Lin, Chih-Hsin Yang
Pageof 24

Showing results (1-10 of 231) with videos related to

Sort By:
Pageof 24
Chinese Clinical Oncology|July 18, 2019
Challenges of the phase I drug development in non-small cell lung cancerChia-Chi Lin
Journal of the Formosan Medical Association = Taiwan Yi Zhi|November 29, 2011
RET mutations and medullary thyroid cancerChia-Chi Lin
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Clinical Development of Colony-Stimulating Factor 1 Receptor (CSF1R) InhibitorsChia-Chi Lin
Cancer Prevention Research (Philadelphia, Pa.)|January 6, 2025
Passing the Torch forward: Moving beyond EGFR Inhibition in NMIBC PreventionTsung-Che Wu, Chia-Chi Lin
Targeted Oncology|April 4, 2009
Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancerChia-Chi Lin, Chih-Hsin Yang
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2022
Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase InhibitorsTsung-Che Wu, Chia-Chi Lin
Trends in Biotechnology|January 4, 2025
Bacterial proteome microarray technology in biomedical researchChia-Chi Lin, Chien-Sheng Chen
Drugs|December 24, 2010
Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutationsChia-Chi Lin, James Chih-Hsin Yang
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Active tuberculosis during temsirolimus and bevacizumab treatmentChia-Chi Lin, Jann-Yuan Wang, Yeong-Shiau Pu
Discovery Medicine|July 1, 2010
Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancerYu-Yun Shao, Chia-Chi Lin, Chih-Hsin Yang
Pageof 24